← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Selective immunosuppressants
apremilast
L04AA32
Forms & Strengths
- Oral tablets: 10 mg, 20 mg, 30 mg
- Starter pack: 10 mg (4), 20 mg (4), 30 mg (19)
Adult Dosing
- Psoriatic arthritis: 30 mg orally twice daily
- Plaque psoriasis: 30 mg orally twice daily
- Behcet's disease: 30 mg orally twice daily
- Renal impairment (severe, CrCl <30 mL/min): 30 mg orally once daily
Pediatric Dosing
- Safety and efficacy not established in pediatric patients <18 years
Indications
- Active psoriatic arthritis
- Moderate to severe plaque psoriasis candidates for phototherapy or systemic therapy
- Oral ulcers associated with Behcet's disease
Mechanism of Action
- Phosphodiesterase 4 (PDE4) inhibitor
- Increases intracellular cAMP levels, modulating inflammatory mediator production
Contraindications
- Known hypersensitivity to apremilast or any excipients
Adverse Reactions
- Diarrhea
- Nausea
- Upper respiratory tract infection
- Tension headache
- Headache
- Weight decrease
- Depression
Drug Interactions
- Strong CYP450 enzyme inducers (e.g., rifampin, carbamazepine, phenobarbital, phenytoin): Decreases apremilast exposure and efficacy; co-administration is not recommended
Curated Content: Needs Vetting Before Put to Clinical Use